Table 5.
Reference | Patients | Immunologic response | Clinical response |
---|---|---|---|
[174] |
n = 11 recurrent GBM |
Local skin reaction | Median survival: 46 weeks |
[175] |
n = 23 GBM |
Delayed-type hypersensitivity, increased memory T cells, increased CD8+ T cells in recurrent tumors | Median progression free survival: 40 weeks, median survival 100 weeks |
[176] |
n = 12 GBM |
— | CR: 1, PR: 1, minor response: 2, median survival: 10.7 mo |